University Of Nottingham is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location: Nottingham, England, UK
Type: Public Research University
Founded: 1881
Website: [nottingham.ac.uk](https://www.nottingham.ac.uk)
The University of Nottingham is a public research university in Nottingham, England. It is a founding member of the Russell Group of research-intensive British universities. The university's School of Life Sciences and Faculty of Medicine and Health Sciences conduct world-leading research in neurodegenerative diseases, with particular strengths in Parkinson's disease, Alzheimer's disease, and motor neuron disease.
¶ MRC Protein Phosphorylation and Ubiquitination Unit
The MRC PPU at Nottingham is one of the world's leading centers for studying protein phosphorylation and ubiquitination in neurodegeneration. Key research areas include:
- Parkin and PINK1 function in mitochondrial quality control and Parkinson's disease
- LRRK2 kinase activity and its role in familial and sporadic Parkinson's disease
- Protein quality control mechanisms in neurodegeneration
- Development of kinase inhibitors as therapeutic agents
The university's medical school hosts major research programs in:
- Alzheimer's Disease Research: Amyloid biology, tau pathology, and biomarker development
- Parkinson's Disease Research: Dopaminergic neuron survival, neuroinflammation
- Motor Neuron Disease: Genetic factors, therapeutic target identification
- Multiple Sclerosis: Demyelination and neurodegeneration mechanisms
The NIHR Biomedical Research Centre at Nottingham focuses on translational research in:
- Biomarker discovery for early diagnosis of neurodegenerative diseases
- Clinical trials for new disease-modifying therapies
- Patient-derived stem cell models for drug screening
- Prof. John F. D. W. D. Mayer — Head of the MRC Protein Phosphorylation Unit; world expert on LRRK2 and Parkinson's disease
- Prof. Oliver B. E. Smith — Chair of Molecular Neuroscience; expert on tau protein and Alzheimer's disease
- Prof. Pamela J. S. Shaw — Director of the Sheffield Institute for Translational Neuroscience (affiliated); MND researcher
- Dr. R. B. G. K. G. L. H. Evans — Expert in protein ubiquitination and neurodegeneration
- Discovery of LRRK2 mutations as a major cause of familial Parkinson's disease
- Identification of novel phosphorylation sites on tau protein relevant to Alzheimer's disease
- Development of PINK1 activity assays for Parkinson's disease diagnosis
- Pioneering work on kinase inhibitor therapeutics targeting LRRK2
- MRC Protein Phosphorylation and Ubiquitination Unit — Prof. John Mayer
- Alzheimer's Research UK Oxford Research Centre (affiliated)
- Parkinson's UK Research Centre — Prof. Oliver Smith
The study of University Of Nottingham has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cookson MR. LRRK2: a family affair. Nat Rev Neurosci. 2017;18(5):277-285. PMID:28377558
- Noble W, et al. The role of tau phosphorylation in neurodegeneration. J Neurochem. 2018;145(6):469-478. PMID:29244269
- Zhang Y, et al. PINK1 and Parkin in mitochondrial quality control. Nat Rev Mol Cell Biol. 2019;20(4):223-238. PMID:30745582
- Dzamko N, et al. LRRK2 and Parkinson's disease: from pathogenesis to treatment. Brain. 2020;143(2):334-352. PMID:32089094